Differences in time to drug initiation and inactive disease achievement by insurance type in patients with nonsystemic juvenile idiopathic arthritis
Elaine Yung, Xiaoxuan Liu, Minal Aundhia, Chen Chen, Michael Wagner, Bin Huang, Hermine I Brunner · 2026
Read Differences in time to drug initiation and inactive disease achievement by insurance type in patients with nonsystemic juvenile idiopathic arthritis by Elaine Yung, Xiaoxuan Liu, Minal Aundhia, Chen Chen, Michael Wagner, Bin Huang, Hermine I Brunner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13269468.txt.
Description
Elaine Yung and co-authors ask in 2026 whether a child's insurance type changes how quickly advanced arthritis drugs start and how soon the disease goes quiet. They studied 968 children newly diagnosed with nonsystemic juvenile idiopathic arthritis at a large center between 2009 and 2020. About four in five had private insurance and the rest public coverage, with nearly six thousand patient-years of follow-up.
Time to starting a biologic or targeted drug was the same for both groups, roughly five months. Publicly insured children, however, arrived with more active disease and took longer to reach inactive disease, about ten months versus seven. The authors say later work must untangle how much of the gap comes from severity at arrival, access, adherence, or family circumstances.
Catalog record
| CREATOR | Elaine Yung, Xiaoxuan Liu, Minal Aundhia, Chen Chen, Michael Wagner, Bin Huang, Hermine I Brunner |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |